EGFR and non-small cell lung carcinoma: In particular, dual‐target PROTACs, such as DP‐V‐4 (co‐degrading PARP and EGFR), have shown potential in combating adaptive resistance in NSCLC, where both single‐target and multi‐target resistance mechanisms are present in the same patient tumors (Cordani et al. 2024).